Common use of Key Achievements Clause in Contracts

Key Achievements. China has agreed to: • Operate a transparent, predictable, efficient, and science- and risk- based regulatory system for products derived from agricultural biotechnology; • Reduce the application review time for products for animal feed or for further processing to no more than 24 months, on average; • Base safety evaluation procedures on relevant international standards and recommendations of the Codex Alimentarius Commission and the International Plant Protection Convention; • Pre-screen each application for regulatory review for completeness and inform the applicant of any deficiencies within five business days; • Accept complaints from applicants concerning the approval procedure and take corrective action upon receipt of a justified complaint; • When additional, necessary information is needed by the National Biosafety Committee (NBC) to finalize an evaluation, within 20 business days of such a determination, request all information in writing and provide a written explanation of how the requested information would be relevant to the safety assessment of the product’s intended use; • When additional information has been submitted to the NBC, ensure that the NBC meets as soon as possible and as often as necessary to finalize the NBC’s review of the application; • Extend product authorizations to five years; • Establish and make public a simplified, predictable, efficient, and science- and risk-based safety assessment procedure for the authorization of food ingredients derived from genetically modified microorganisms; • Accept product applications on an ongoing, year-round basis and begin review upon receipt of the formal application; • Not request information unnecessary for assessing the safety of the product for its intended use; and • For products authorized, issue a biosafety certificate within 20 business days of the conclusion of a NBC meeting. • In the event of a LLP occurrence, China will: o Without undue delay, inform the importer of the LLP occurrence and any pertinent information that will be required to assist China to decide on the management of the LLP occurrence; o Conduct evaluation on inadvertent or technically unavoidable LLP occurrences on a case-by-case basis to minimize trade disruptions; o Provide to the United States a summary of any risk or safety assessment that China conducted in association with the LLP occurrence; o Ensure that the LLP occurrence is managed without unnecessary delay; and o Consider any relevant risk or safety assessment provided and authorization granted by the United States or any foreign country when deciding how to manage the LLP occurrence. • Work with the United States to strengthen communication on biotechnology regulation, to increase mutual understanding, and to monitor implementation of this agreement.

Key Achievements. China has agreed to: •  Operate a transparent, predictable, efficient, and science- and risk- based regulatory system for products derived from agricultural biotechnology; •  Reduce the application review time for products for animal feed or for further processing to no more than 24 months, on average; •  Base safety evaluation procedures on relevant international standards and recommendations of the Codex Alimentarius Commission and the International Plant Protection Convention; •  Pre-screen each application for regulatory review for completeness and inform the applicant of any deficiencies within five business days; •  Accept complaints from applicants concerning the approval procedure and take corrective action upon receipt of a justified complaint; •  When additional, necessary information is needed by the National Biosafety Committee (NBC) to finalize an evaluation, within 20 business days of such a determination, request all information in writing and provide a written explanation of how the requested information would be relevant to the safety assessment of the product’s intended use; •  When additional information has been submitted to the NBC, ensure that the NBC meets as soon as possible and as often as necessary to finalize the NBC’s review of the application; •  Extend product authorizations to five years; •  Establish and make public a simplified, predictable, efficient, and science- and risk-based safety assessment procedure for the authorization of food ingredients derived from genetically modified microorganisms; •  Accept product applications on an ongoing, year-round basis and begin review upon receipt of the formal application; •  Not request information unnecessary for assessing the safety of the product for its intended use; and •  For products authorized, issue a biosafety certificate within 20 business days of the conclusion of a NBC meeting. •  In the event of a LLP occurrence, China will: o Without undue delay, inform the importer of the LLP occurrence and any pertinent information that will be required to assist China to decide on the management of the LLP occurrence; o Conduct evaluation on inadvertent or technically unavoidable LLP occurrences on a case-by-case basis to minimize trade disruptions; o Provide to the United States a summary of any risk or safety assessment that China conducted in association with the LLP occurrence; o Ensure that the LLP occurrence is managed without unnecessary delay; and o Consider any relevant risk or safety assessment provided and authorization granted by the United States or any foreign country when deciding how to manage the LLP occurrence. •  Work with the United States to strengthen communication on biotechnology regulation, to increase mutual understanding, and to monitor implementation of this agreement.